CL2015002624A1 - Agentes quelantes de precursores de producto final de glicación avanzada (age) - Google Patents

Agentes quelantes de precursores de producto final de glicación avanzada (age)

Info

Publication number
CL2015002624A1
CL2015002624A1 CL2015002624A CL2015002624A CL2015002624A1 CL 2015002624 A1 CL2015002624 A1 CL 2015002624A1 CL 2015002624 A CL2015002624 A CL 2015002624A CL 2015002624 A CL2015002624 A CL 2015002624A CL 2015002624 A1 CL2015002624 A1 CL 2015002624A1
Authority
CL
Chile
Prior art keywords
agents
age
end product
advanced glycation
glycation end
Prior art date
Application number
CL2015002624A
Other languages
English (en)
Spanish (es)
Inventor
Stephen Randall Holmes-Farley
Pradeep Dhal
Magnus Besev
Robert J Miller
Andrew T Papoulis
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of CL2015002624A1 publication Critical patent/CL2015002624A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08FMACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F126/00Homopolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen
    • C08F126/02Homopolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen by a single or double bond to nitrogen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/74Synthetic polymeric materials
    • A61K31/785Polymers containing nitrogen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/12Ophthalmic agents for cataracts
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/04Chelating agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Polymers & Plastics (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Toxicology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Steroid Compounds (AREA)
CL2015002624A 2013-03-15 2015-09-11 Agentes quelantes de precursores de producto final de glicación avanzada (age) CL2015002624A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361792719P 2013-03-15 2013-03-15

Publications (1)

Publication Number Publication Date
CL2015002624A1 true CL2015002624A1 (es) 2016-03-11

Family

ID=50439508

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2015002624A CL2015002624A1 (es) 2013-03-15 2015-09-11 Agentes quelantes de precursores de producto final de glicación avanzada (age)

Country Status (24)

Country Link
US (2) US20160024233A1 (https=)
EP (1) EP2968403A1 (https=)
JP (4) JP2016512830A (https=)
KR (1) KR20150130492A (https=)
CN (1) CN105188718A (https=)
AR (1) AR095593A1 (https=)
AU (2) AU2014235500A1 (https=)
BR (1) BR112015023404A8 (https=)
CA (1) CA2906501A1 (https=)
CL (1) CL2015002624A1 (https=)
CR (1) CR20150545A (https=)
DO (1) DOP2015000221A (https=)
EA (1) EA201591733A1 (https=)
HK (1) HK1220607A1 (https=)
IL (1) IL241406A0 (https=)
MA (1) MA38487A1 (https=)
MX (1) MX2015012843A (https=)
PE (1) PE20151766A1 (https=)
PH (1) PH12015502019A1 (https=)
SG (2) SG10201707590XA (https=)
TN (1) TN2015000390A1 (https=)
TW (1) TW201521744A (https=)
UY (1) UY35441A (https=)
WO (1) WO2014150873A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA41202A (fr) * 2014-12-18 2017-10-24 Genzyme Corp Copolymères polydiallymine réticulé pour le traitement du diabète de type 2
CN111405870A (zh) * 2017-08-31 2020-07-10 西托索尔本茨公司 从体液中降低晚期糖基化终末产物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5985938A (en) * 1997-11-05 1999-11-16 Geltex Pharmaceuticals, Inc. Method for reducing oxalate
CA2444046C (en) * 2001-04-18 2011-06-07 Steven K. Burke Use of colesevelam in reducing serum glucose
AU2003263010A1 (en) * 2003-09-02 2005-04-21 Genzyme Corporation Method for reducing vascular inflammation
US7459502B2 (en) * 2003-11-03 2008-12-02 Ilypsa, Inc. Pharmaceutical compositions comprising crosslinked polyamine polymers
US7385012B2 (en) * 2003-11-03 2008-06-10 Ilypsa, Inc. Polyamine polymers
AU2005214971A1 (en) * 2004-02-17 2005-09-01 Dynamis Therapeutics, Inc. Fructoseamine 3 kinase and the formation of collagen and elastin
FR2883873B1 (fr) * 2005-03-31 2009-07-10 Pharmamens Sarl Inhibiteurs d'age
WO2011106542A2 (en) * 2010-02-24 2011-09-01 Relypsa, Inc. Crosslinked polyvrnylamine, poly all ylamine, and polyethyleneimine for use as bile acid sequestrants

Also Published As

Publication number Publication date
IL241406A0 (en) 2015-11-30
KR20150130492A (ko) 2015-11-23
EP2968403A1 (en) 2016-01-20
WO2014150873A1 (en) 2014-09-25
JP2016512830A (ja) 2016-05-09
CA2906501A1 (en) 2014-09-25
SG10201707590XA (en) 2017-11-29
US20180265613A1 (en) 2018-09-20
PE20151766A1 (es) 2015-12-11
PH12015502019A1 (en) 2016-01-11
EA201591733A1 (ru) 2016-01-29
US20160024233A1 (en) 2016-01-28
JP2018135365A (ja) 2018-08-30
MA38487A1 (fr) 2017-12-29
BR112015023404A8 (pt) 2019-12-03
TW201521744A (zh) 2015-06-16
JP2022037143A (ja) 2022-03-08
DOP2015000221A (es) 2015-12-15
MX2015012843A (es) 2016-08-08
UY35441A (es) 2014-10-31
CR20150545A (es) 2015-12-01
BR112015023404A2 (pt) 2017-07-18
HK1220607A1 (zh) 2017-05-12
AR095593A1 (es) 2015-10-28
TN2015000390A1 (en) 2017-01-03
JP2020055850A (ja) 2020-04-09
CN105188718A (zh) 2015-12-23
AU2019201259A1 (en) 2019-03-14
SG11201506413PA (en) 2015-09-29
AU2014235500A1 (en) 2015-11-05

Similar Documents

Publication Publication Date Title
IL257507B (en) Compounds and methods for transferring through the membranes of molecules
EP3490622A4 (en) METHODS AND COMPOSITIONS FOR Wounds Healing
EP4303288C0 (en) PROCESSES FOR PRODUCING INDUSTRIAL PRODUCTS FROM VEGETABLE LIPIDS
MX394081B (es) Método para preparar un producto lácteo que tiene un contenido estable de galactooligosacárido (s).
CL2016003198A1 (es) Composiciones y métodos para empacar productos
CL2016000378A1 (es) Composiciones y métodos terapéuticos para la regresión acelerada de placa
CL2016001587A1 (es) Derivado basado en 1,2-naftoquinona y método de preparación del mismo.
MX2020009444A (es) Composicion farmaceutica oral de isotretinoina con dosis baja y su proceso de preparacion.
BR112017025427A2 (pt) composição farmacêutica oral
MA40313A (fr) Composition pharmaceutique à base d'isotrétinoïne destinée à la voie orale
CO2017004650A2 (es) Método de ajuste de la composición de productos de cromatografía
PT2947996T (pt) Método para produzir composições de beta-caseína e produtos relacionados
BR112015014870A2 (pt) método para embalar produtos e aparelho para embalar produtos
BR112015023678A2 (pt) métodos e aparelho para produzir meios pontuados, e artigo e composições que resultam dos mesmos
BR112015001564A2 (pt) métodos para a remoção de um ou mais componentes de uma composição ou composições.
MX2017001331A (es) Composicion farmaceutica oral de isotretinoina.
ZA201804525B (en) Gypsum product composition, gypsum products, and a method for using a compound in gypsum board
MA40312A (fr) Composition pharmaceutique orale d'isotrétinoïne
CL2015002624A1 (es) Agentes quelantes de precursores de producto final de glicación avanzada (age)
BR112019002729A2 (pt) composição farmacêutica sólida e processo para preparar uma composição farmacêutica sólida
BR112017006613A2 (pt) composição herbicida e processo da mesma
BR112016030705B8 (pt) Lipídeo de planta extraído e composição compreendendo o referido lipídeo
HUP1400025A1 (en) New dhydro-oxazinobenzodiazepine compounds a process for their preparation and pharmaceutical compositions containing them
MX369174B (es) Proceso para la preparación de un compuesto.
BR112016019395A2 (pt) composição